Search
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalEfmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII … immunoglobulin G1, a long-lived plasma protein [FDA Label].
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigational[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding … Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol].
Mixtures: ACTIVA DE +TABLETAS RECUBIERTASAtomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … [A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which
Products: ATOMOXE 1A PHARMA 10MG, ATOMOXE 1A PHARMA 18MGBexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Categories: Compounds used in a research, industrial, or household settingSecretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalAlthough it is a gastrointestinal hormone, secretin is also considered as a neuropeptide hormone since it is also expressed in the central nervous system [A32275]. … Human secretin is a gastrointestinal peptide hormone that regulates secretions in the stomach, pancreas, and liver.
Nitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179824] Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole].[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.
Products: AA-Nitrofurantoin Tablet 100mgIopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. … angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography
Categories: Compounds used in a research, industrial, or household settingTeniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalTeniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. … This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.
Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]